Skip to main content

CITADEL ADVISORS LLC

Position in AARD — Aardvark Therapeutics, Inc.

CIK 1423053 MIAMI, FL

Position in AARD

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$4,685,269
-$12,236,307 QoQ
Shares Held
1,242,777
-3.6% QoQ
Ownership
5.70%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Mar 2025
5 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in AARD Over Time

Shares Held

Position Value (USD)

Derivatives in AARD

reported options exposure · as of Mar 31, 2026
CallValue
$0
CallShares
0
PutValue
$199,433
PutShares
52,900

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

CITADEL ADVISORS LLC holds $5,784,241,435 across 374 Biotechnology names. AARD ranks #129 (0.1% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in AARD

Export CSV
7 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $199,433 52,900
2026-03-31 $4,685,269 1,242,777
2025-12-31 $16,921,576 1,289,263
2025-09-30 $18,072,844 1,359,883
2025-06-30 $17,356,056 1,283,732
2025-03-31 $9,568,370 1,274,084
2025-02-14 $15,866,514 1,192,971